Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study
- 152 Downloads
The aims of this study were to analyze the maxillomandibular morphology of patients with mucopolysaccharidosis (MPS) type I, II, III, IVa and VI and to evaluate the craniofacial effect of hematopoietic stem cell transplantation (HCST) in MPS I.
Materials and methods
One hundred head magnetic resonance images were retrospectively analyzed from 41 MPS and 27 control individuals. The width, height and length of the maxilla and mandible were plotted against age and the means of controls, MPS I, MPS II and MPS III were statistically compared. To determine the effect of HSCT in MPS I, jaw morphology was compared between MPS I patients with full donor chimerism versus patients with mixed/no donor chimerism.
Maxillary dimensions were not statistically different between the MPS types. The height and length of the mandible were clearly smaller in MPS I as compared to those in controls, MPS II and MPS III. This was associated with progressive resorption of the mandibular condyles in MPS I, which was also observed in MPS II and VI, but not in MPS III or IVa. Whereas the success of HCST did not affect these changes, mandibular width was significantly smaller in MPS I individuals with full donor chimerism.
MPS I individuals have a smaller mandible as compared to control, MPS II and MPS III individuals due to progressive condylar degeneration. These abnormalities are also evident following successful HSCT.
Clinicians should be aware of specific differences in mandibular morphology and condylar involvement among the MPS subtypes.
KeywordsMucopolysaccharidosis MRI Craniofacial Cephalometry OSAS Hematopoetic stem cell transplantation
This research received no specific grant from any funding agency.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All analyses were performed retrospectively on routinely acquired images and all data were fully anonymized before analysis. Therefore, in accordance with the federal hospital laws (Hamburgisches Krankenhausgesetz) no approval by the local ethics committee was necessary.
For this type of study formal consent is not required.
- 2.Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M, Kida K, Shibata Y, Futatsumori H, Montano AM, Mason RW, Yamaguchi S, Suzuki Y, Orii T (2013) Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 110(1–2):42–53. https://doi.org/10.1016/j.ymgme.2013.06.007 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, Mengel E, Offringa M, O'Meara A, Parini R, Rovelli A, Sykora KW, Valayannopoulos V, Vellodi A, Wynn RF, Wijburg FA (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6:55. https://doi.org/10.1186/1750-1172-6-55 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Clarke LA (1993) Mucopolysaccharidosis type I. In: Pagon RA, Adam MP, Ardinger HH et al. (eds) GeneReviews(R). Seattle (WA)Google Scholar
- 8.Ribeiro EM, Fonteles CS, Freitas AB, da Silva Alves KS, Monteiro AJ, da Silva CA (2015) A clinical multicenter study of orofacial features in 26 Brazilian patients with different types of mucopolysaccharidosis. Cleft Palate Craniofac J 52(3):352–358. https://doi.org/10.1597/13-204 CrossRefPubMedGoogle Scholar
- 10.Pal AR, Brown N, Jones SA, Bigger BW, Bruce IA (2015) Obstructive sleep apnea in MPS: a systematic review of pretreatment and posttreatment prevalence and severity. J Inborn Errors Metab Screen 1-10. DOI: 10.1177/2326409815616392. Google Scholar
- 12.Kantaputra PN, Kayserili H, Guven Y, Kantaputra W, Balci MC, Tanpaiboon P, Tananuvat N, Uttarilli A, Dalal A (2014) Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet A 164A(6):1443–1453. https://doi.org/10.1002/ajmg.a.36489 CrossRefPubMedGoogle Scholar
- 16.Savara BS, Singh IJ (1968) Norms of size and annual increments of seven anatomical measures of maxillae in boys from three to sixteen years of age. Angle Orthod 38(2):104–120. https://doi.org/10.1043/0003-3219(1968)038<0104:NOSAAI>2.0.CO;2 PubMedGoogle Scholar
- 20.Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tylee KL, Wynn RF, Wijburg FA, Jones SA, Bruce IA, Bigger BW (2015) Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis 10:42. https://doi.org/10.1186/s13023-015-0255-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.de Santana Sarmento DJ, de Carvalho SH, Melo SL, Fonseca FR, Diniz DN, Bento PM, Mesquita Gde Q, de Melo DP (2015) Mucopolysaccharidosis: radiographic findings in a series of 16 cases. Oral Surg Oral Med Oral Pathol Oral Radiol 120(6):e240–e246. https://doi.org/10.1016/j.oooo.2015.08.009 CrossRefPubMedGoogle Scholar
- 30.Cavaleiro RM, Pinheiro M, Pinheiro LR, Tuji FM, Feio Pdo S, de Souza IC, Feio RH, de Almeida SC, Schwartz IV, Giugliani R, Pinheiro JJ, Santana-da-Silva LC (2013) Dentomaxillofacial manifestations of mucopolysaccharidosis VI: clinical and imaging findings from two cases, with an emphasis on the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol 116(2):e141–e148. https://doi.org/10.1016/j.oooo.2013.04.021 CrossRefPubMedGoogle Scholar
- 35.Fjeld M, Arvidsson L, Smith HJ, Flato B, Ogaard B, Larheim T (2010) Relationship between disease course in the temporomandibular joints and mandibular growth rotation in patients with juvenile idiopathic arthritis followed from childhood to adulthood. Pediatr Rheumatol Online J 8:13. https://doi.org/10.1186/1546-0096-8-13 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Schmidt M, Breyer S, Lobel U, Yarar S, Stucker R, Ullrich K, Muller I, Muschol N (2016) Musculoskeletal manifestations in mucopolysaccharidosis type I (hurler syndrome) following hematopoietic stem cell transplantation. Orphanet J Rare Dis 11(1):93. https://doi.org/10.1186/s13023-016-0470-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, Bleyzac N, Mulier C, Durin A, Kebaili K, Galambrun C, Bertrand Y, Froissart R, Dorche C, Gebuhrer L, Garin C, Berard J, Guibaud P (2003) Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 31(12):1105–1117. https://doi.org/10.1038/sj.bmt.1704105 CrossRefPubMedGoogle Scholar
- 41.Kuehn SC, Koehne T, Cornils K, Markmann S, Riedel C, Pestka JM, Schweizer M, Baldauf C, Yorgan TA, Krause M, Keller J, Neven M, Breyer S, Stuecker R, Muschol N, Busse B, Braulke T, Fehse B, Amling M, Schinke T (2015) Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I. Hum Mol Genet 24(24):7075–7086. https://doi.org/10.1093/hmg/ddv407 PubMedGoogle Scholar
- 42.Hartung SD, Frandsen JL, Pan D, Koniar BL, Graupman P, Gunther R, Low WC, Whitley CB, McIvor RS (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9(6):866–875. https://doi.org/10.1016/j.ymthe.2004.03.011 CrossRefPubMedGoogle Scholar
- 43.Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, Braunlin EA (2017) Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis 40(2):281–289. https://doi.org/10.1007/s10545-016-9988-z CrossRefPubMedGoogle Scholar
- 44.Visigalli I, Delai S, Politi LS, Di Domenico C, Cerri F, Mrak E, D'Isa R, Ungaro D, Stok M, Sanvito F, Mariani E, Staszewsky L, Godi C, Russo I, Cecere F, Del Carro U, Rubinacci A, Brambilla R, Quattrini A, Di Natale P, Ponder K, Naldini L, Biffi A (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116(24):5130–5139. https://doi.org/10.1182/blood-2010-04-278234 CrossRefPubMedPubMedCentralGoogle Scholar